Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data.

Valle, Juan W;Borbath, Ivan;Rosbrook, Brad;Fernandez, Kathrine;Raymond, Eric
(2019) Future Oncology — Vol. 15, n° 11, p. 1219-1230 (2019)

Files

2019_Valle_Future_Oncol.pdf
  • Open Access
  • Adobe PDF
  • 1.44 MB
Download

Details

Authors
  • Valle, Juan W
    Author
  • Borbath, IvanUCLouvain
    Author
  • Rosbrook, Brad
    Author
  • Fernandez, Kathrine
    Author
  • Raymond, Eric
    Author
Abstract
(en) AIM: To describe the long-term safety of sunitinib in patients with progressive, well-differentiated, advanced/metastatic pancreatic neuroendocrine tumors. PATIENTS & METHODS: Sunitinib- and placebo-treated patients from the Phase III study continued to receive sunitinib (37.5 mg on a continuous daily-dosing regimen) in two open-label extension studies. RESULTS: Median (range) treatment exposure: 30.2 (0.7-269.4) and 87.1 (3.9-319.4) weeks for medium-term (n = 41) and long-term-treated (n = 61) populations, respectively. All patients experienced ≥1 adverse event (AE); 47 (45.6%) reported serious AEs. Common all-causality AEs: diarrhea (63.1%); neutropenia (43.7%); abdominal pain (40.8%). Fifteen (14.6%) patients discontinued treatment due to treatment-related AEs. CONCLUSION: The safety of extended sunitinib treatment was consistent with the known safety profile of sunitinib in pancreatic neuroendocrine tumors.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Valle, J. W., Borbath, I., Rosbrook, B., Fernandez, K., & Raymond, E. (2019). Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data. Future Oncology, 15(11), 1219-1230. https://doi.org/10.2217/fon-2018-0882 (Original work published 2019)